Burning Rock Biotech Limited(BNR)Earnings, Financials & Key Ratios
BNR•NASDAQ
$8.96
Price updated Jul 2, 2026
AboutBurning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.Show more
- Revenue$540M+4.6%
- EBITDA-$33M+89.2%
- Net Income-$55M+84.0%
- EPS (Diluted)-49.60-47.3%
- Gross Margin74.67%+6.3%
- EBITDA Margin-6.13%+89.6%
- Operating Margin-10.16%+85.3%
- Net Margin-10.26%+84.7%
- ROE-9.91%+80.7%
BNR Price & Volume
Burning Rock Biotech Limited (BNR) stock price & volume — 10-year historical chart
Loading chart...
Operational Efficiency Gains Offset Stagnant Revenue Growth
Investment Thesis • Updated 2025Q4
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Adequate
Cash Flow:Improving
Primary Risk:Regulatory pricing and VBP
Key Thesis Takeaways
- Burning Rock Biotech is navigating a challenging transition from aggressive expansion to disciplined capital management, evidenced by a significant reduction in operating losses from $178.8M in 2023Q3 to $12.0M in 2025Q4.
- While the company has successfully improved gross margins to 78.0%, future growth remains constrained by intense competition and regulatory pricing pressures within the Chinese oncology market.
- Investors should monitor the sustainability of the recent $17.8M free cash flow inflection against the backdrop of a $4.3 billion accumulated deficit and ongoing working capital volatility.
Verdict Logic
while the company has achieved a positive $17.8M free cash flow in 2025Q4, the stagnant 0.2% revenue growth and $4.3 billion accumulated deficit suggest that long-term profitability remains highly speculative.
BNR Growth Metrics
Burning Rock Biotech Limited (BNR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years4.65%
3 Years-1.42%
TTM4.6%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM84.03%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM84.63%
Return on Capital
10 Years-46.23%
5 Years-45.89%
3 Years-43%
Last Year-9.2%
BNR Recent Earnings
Burning Rock Biotech Limited (BNR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (88%)●Beat Revenue 2/12 qtrs (50%)
Q3 2026Latest
Jun 9, 2026Metric
Actual
Est
EPS
$0.20+91.3%
$2.29
Rev
$16M-18.3%
$19M
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.21+85.0%
$1.40
Rev
$18M
—
Q4 2025
Nov 20, 2025Metric
Actual
Est
EPS
$0.26
—
Rev
$18M
—
Q4 2025
Sep 8, 2025Metric
Actual
Est
EPS
$0.15
—
Rev
$21M
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 9, 2026 | $0.20vs $2.29+91.3% | $16Mvs $19M-18.3% |
| Q2 2026 | Mar 12, 2026 | $0.21vs $1.40+85.0% | $18M |
| Q4 2025 | Nov 20, 2025 | $0.26 | $18M |
| Q4 2025 | Sep 8, 2025 | $0.15 | $21M |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Burning Rock Biotech Limited (BNR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.96 | $9.47M | -1.23 | 4.6% | -10.26% | -9.91% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $170.77 | $22.64B | -51.44 | 32.88% | -40.1% | — | — | |
| $276.27 | $39.57B | -181.76 | 35.9% | -9.05% | -15.13% | — | |
| $117.16 | $7.76B | 85.52 | 15.24% | 9.48% | 5.13% | — | |
| $183.89 | $27.93B | 33.74 | -0.78% | 19.43% | 32.84% | — |
Compare BNR vs Peers
Burning Rock Biotech Limited (BNR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when BNR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BNR Frequently Asked Questions
Burning Rock Biotech Limited (BNR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Burning Rock Biotech Limited's revenue?
Burning Rock Biotech Limited (BNR) reported $539.6M in revenue for fiscal year 2025. This represents a 385% increase from $111.2M in 2017.
How fast is Burning Rock Biotech Limited growing?
Burning Rock Biotech Limited (BNR) grew revenue by 4.6% over the past year. Growth has been modest.
Is BNR profitable?
Burning Rock Biotech Limited (BNR) reported a net loss of $55.3M for fiscal year 2025.
Dividend & Returns
What is BNR's return on equity?
Burning Rock Biotech Limited (BNR) has a return on equity (ROE) of -9.9%. Negative ROE indicates the company is unprofitable.
What is Burning Rock Biotech Limited's free cash flow?
Burning Rock Biotech Limited (BNR) had negative free cash flow of $33.7M in fiscal year 2025, likely due to heavy capital investments.